Wells Fargo Upgrades Viridian Therapeutics to Overweight, Raises Price Target to $31

Wells Fargo analyst Derek Archila upgrades Viridian Therapeutics (NASDAQ: VRDN ) from Equal-Weight to Overweight and raises the price target from $20 to $31.